Home    中文  
 
  • Search
  • lucene Search
  • Citation
  • Fig/Tab
  • Adv Search
Just Accepted  |  Current Issue  |  Archive  |  Featured Articles  |  Most Read  |  Most Download  |  Most Cited

Chinese Journal of Kidney Disease Investigation(Electronic Edition) ›› 2012, Vol. 01 ›› Issue (02): 98-102. doi: 10.3877/cma.j.issn.2095-3216.2012.02.008

• Expert Forum • Previous Articles     Next Articles

Evidence-based treatment for Henoch-Schonlein purpura nephritis

Li-li XU1, Wei-ming WANG1,()   

  1. 1.Renal Division, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China
  • Received:2012-11-08 Online:2012-12-18 Published:2024-12-06
  • Contact: Wei-ming WANG

Abstract:

Clinical manifestations of Henoch-Schonlein purpura nephritis (HSPN) are diverse,with respiratory and digestive system damage. Children incidence is higher than adults' incidence which is increasing year by year. The prognosis of HSPN is associated with clinical manifestations (proteinuria,hematuria) and pathological severity. Kidney Disease: Improving Global Outcomes (KIDGO) guideline has released the HSPN standardized diagnosis and treatment plan according to evidence-based medicine.The recommended therapy for HSPN patients with persistent proteinuria [0.5 - 1.0 g/(d . 1.73 m2)] is angiotensin-converting enzyme inhibitor (ACEI) or angiotensin receptor antagonist (ARB). And severe patients who still show persistent proteinuria [>1 g/(d . 1.73 m2)]with GFR over 50 ml/(min . 1.73 m2) after treatment with ACEI or ARBs, should be added with a 6-month course of corticosteroid therapy.

Key words: Henoch-Schonlein purpura nephritis, Treatment

京ICP 备07035254号-35
Copyright © Chinese Journal of Kidney Disease Investigation(Electronic Edition), All Rights Reserved.
Tel: 010-66937011 E-mail: zhsbyj@126.com
Powered by Beijing Magtech Co. Ltd